Back to User profile » Mr David Chandiwana

Papers published by Mr David Chandiwana:

Original Research

Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2− Advanced Breast Cancer

Fasching PA, Delea TE, Lu YS, De Boer R, Hurvitz SA, Moynahan A, Chandiwana D, Lanoue B, Hu H, Thuerigen A, O'Shaughnessy J

Cancer Management and Research 2021, 13:8179-8189

Published Date: 1 November 2021

Original Research

Matching-adjusted indirect treatment comparison of ribociclib and palbociclib in HR+, HER2− advanced breast cancer

Tremblay G, Chandiwana D, Dolph M, Hearnden J, Forsythe A, Monaco M

Cancer Management and Research 2018, 10:1319-1327

Published Date: 22 May 2018

Original Research

Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G

Breast Cancer: Targets and Therapy 2018, 10:69-78

Published Date: 4 May 2018

Original Research

Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?

Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Shor A, Tremblay G

Cancer Management and Research 2018, 10:1015-1025

Published Date: 4 May 2018